Real-world efficacy and safety of apremilast monotherapy in the management of moderate-to-severe Psoriasis
Introduction: Apremilast is the new oral drug in the management of moderate-to-severe plaque psoriasis with well-established effectiveness and safety in long-term clinical trials and a few real-world studies. However, its effectiveness and safety in Indian setup have not been reported yet. Materials...
Saved in:
Main Authors: | Bela J Shah (Author), Deval Mistry (Author), Navin Chaudhary (Author), Shikha Shah (Author) |
---|---|
Format: | Book |
Published: |
Wolters Kluwer Medknow Publications,
2020-01-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Apremilast in people living with HIV with psoriasis vulgaris: A case report
by: Bela J Shah, et al.
Published: (2019) -
Apremilast in the therapy of moderate-to-severe chronic plaque psoriasis
by: Gisondi P, et al.
Published: (2016) -
The Use of Apremilast in Psoriasis: An Indian Perspective on Real-World Scenarios
by: Rajagopalan M, et al.
Published: (2021) -
A Real-World Evaluation of the Long-Term Safety and Efficacy of Infliximab in the Treatment Moderate-to-Severe Psoriasis
by: Emily K. Haque, et al.
Published: (2020) -
A Comparative Study of the Efficacy of Methotrexate versus Methotrexate with Apremilast in Moderate to Severe Chronic Plaque Psoriasis
by: Divyanshu Srivastava, et al.
Published: (2023)